Observed molecular effects are dependent on experimental design, concentration, and model system and are used to investigate IGF-1 receptor signalling rather than defined biological or physiological outcomes
Are you a manufacturer or trade company
Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly
Nausea (most common, especially during first 1 to 2 weeks of a new dose) Diarrhea or, just as often, constipation Vomiting (less common but more likely at 9 to 12 mg) Reduced appetite, food noise quieting down (this is the goal, not a side effect) Skin sensitivity (dysesthesia): tingling, prickly feeling, or sunburn-like skin
While we do not promise results or make medical claims, we can share what people commonly hope to support
These side effects can impact patient tolerability and adherence, potentially limiting the widespread adoption of these drugs in some individuals